IPHA · Innate Pharma ADR
United States · RS rating 14 · As of 2026-10-14
| Price | 1.43 USD |
|---|---|
| 1-day change | -2.7% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 9 / 20 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 12 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.6% |
| Market cap (USD) | $128.5M |